Catherine Broome, MD, Lombardi Cancer Center, Washington, DC, discusses the developments in the treatment landscape for warm autoimmune hemolytic anemia (WAHA). Current investigations into Bruton’s tyrosine kinase (BTK) inhibitors and spleen tyrosine kinase (SYK) inhibitors will hopefully improve the current armamentarium of treatments for WAHA. Dr Broome additionally comments on neonatal Fc receptor (FcRn)-agonists, which have shown promise in preliminary trials. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.